ABBOTT LABORATORIES Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31)
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) of $1.00 million for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-08.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax · last filed 2013-05-08
- ABBOTT LABORATORIES other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for the quarter ending 2013-03-31 was $1.00M, a 75.00% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), reclassification adjustment on derivatives included in net income, tax (deprecated 2013-01-31) for the quarter ending 2012-03-31 was $4.00M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax (Deprecated 2013-01-31) 3 month |
|---|---|
| 2013-03-31 | $1.00M 10-Q · filed 2013-05-08 |
| 2012-03-31 | $4.00M 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |